Celcuity (CELC) announced the FDA agreed to accept its new drug application for gedatolisib in HR+/HER2- advanced breast cancer for review under the Real-Time Oncology Review program, which facilitates earlier submission of topline efficacy and safety results, prior to the submission of the complete application, to support an earlier start to the FDA’s evaluation of the application. Celcuity is expected to initiate in September a rolling submission to the FDA of its NDA for gedatolisib, based on topline data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. Completion of the NDA submission is targeted for the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity price target raised to $66 from $50 at H.C. Wainwright
- Celcuity’s Geda Triplet Therapy Shows Promising Phase III Results, Justifying Buy Rating
- Celcuity’s Strong Prospects: Buy Rating Affirmed Amidst Positive Drug Developments and Robust Financial Position
- Celcuity Inc. Reports Promising Q2 2025 Results
- Celcuity reports Q2 EPS (93c), consensus (85c)